Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$131.49 USD

131.49
142,467

-0.94 (-0.71%)

Updated Oct 15, 2024 04:00 PM ET

After-Market: $131.54 +0.05 (0.04%) 5:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Haemonetics (HAE) Q1 Earnings Top Estimates, 2024 View Up

by Zacks Equity Research

The robust volume growth and price benefits in the Plasma business drive Haemonetics' (HAE) fiscal first-quarter performance.

QIAGEN (QGEN) Receives FDA Approval for AYVAKIT CDX Test

by Zacks Equity Research

QIAGEN's (QGEN) latest approval adds to its leading portfolio in precision medicine, including 12 FDA-approved companion diagnostics.

Inogen (INGN) Q2 Earnings Beat Estimates, Revenues Down Y/Y

by Zacks Equity Research

Despite higher domestic business-to-business sales and rental revenues, Inogen's (INGN) overall second-quarter results reflect soft performances.

Here's Why You Should Invest in Medtronic (MDT) Stock Now

by Zacks Equity Research

Investors are optimistic about Medtronic (MDT) on strong growth prospects within the Neurosurgery portfolio and upbeat 2024 guidance.

OPKO Health (OPK) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall second-quarter results reflect soft performances.

Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Q2 Loss

by Zacks Equity Research

Strong testing volume improvement across all businesses drives Myriad Genetics' (MYGN) Q2 performance.

Bio-Rad (BIO) Beats on Q2 Earnings Estimates, Cuts 2023 View

by Zacks Equity Research

Growth across the Life Science portfolio and strong double-digit growth for ddPCR drive Bio-Rad (BIO) Q2 performance.

AMN Healthcare (AMN) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

AMN Healthcare's (AMN) dismal results in all its segments led to a soft overall Q2 performance.

DaVita (DVA) Tops Q2 Earnings Estimates, Ups FY23 EPS View

by Zacks Equity Research

DaVita's (DVA) robust dialysis patient service drives its second-quarter performance.

Teleflex (TFX) Q2 Earnings Top Estimates, 2023 Sales View Up

by Zacks Equity Research

Strong performances in its Vascular, Interventional and Surgical businesses drives Teleflex (TFX) Q2 revenues.

PacBio (PACB) Tops on Q2 Earnings, Raises FY23 Revenue View

by Zacks Equity Research

PacBio (PACB) witnesses strong revenue growth in the second quarter, partly aided by customers' product transition to the Revio system.

Surmodics (SRDX) Q3 Earnings Top Estimates, FY23 View Up

by Zacks Equity Research

Surmodics (SRDX) reports a solid fiscal third quarter top line on the back of robust Medical Device revenues.

BD (BDX) Q3 Earnings Surpass Estimates, Margins Contract

by Zacks Equity Research

BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal third quarter.

Nevro (NVRO) Q2 Earnings Lag Estimates, FY23 View Cut

by Zacks Equity Research

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in the second quarter owing to robust domestic and international performances.

Inspire Medical (INSP) Q2 Earnings & Revenues Top Estimates

by Zacks Equity Research

Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the second quarter.

Ecolab (ECL) Q2 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

Ecolab's (ECL) robust performance across all segments drives its Q2 sales, despite business challenges.

Integer Holdings (ITGR) Q2 Earnings Top Estimates, FY23 View Up

by Zacks Equity Research

Integer Holdings' (ITGR) second-quarter results reflect robust Medical and Non-Medical Sales, besides strength in all the product lines.

Compared to Estimates, Integer (ITGR) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Integer (ITGR) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Integer (ITGR) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Integer (ITGR) delivered earnings and revenue surprises of 15.15% and 8.99%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

ITGR or GMED: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ITGR vs. GMED: Which Stock Is the Better Value Option?

Analysts Estimate Hologic (HOLX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Hologic (HOLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Integer (ITGR) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Integer Holdings (ITGR) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Integer Holdings' (ITGR) solid foothold in the broader MedTech space.

Here's Why You Should Hold Integer Holdings (ITGR) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and a solid foothold in the broader MedTech space.